Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorio Reig Jofre's gross profit for the
three
months ended in Jun. 2026 was €57.7 Mil. Laboratorio Reig Jofre's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was €253.7 Mil.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Laboratorio Reig Jofre had a gross margin of 70.18% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Laboratorio Reig Jofre Gross Profit Related Terms
Laboratorio Reig Jofre Gross Profit Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:RJF vs ZTS, UTHR, VTRS: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorio Reig Jofre's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorio Reig Jofre Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorio Reig Jofre's Gross Profit distribution charts can be found below:
* The bar in red indicates where Laboratorio Reig Jofre's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €253.7 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Laboratorio Reig Jofre (XMAD:RJF) has a Gross Profit of €253.7 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on Laboratorio Reig Jofre and its competitors.
Is Laboratorio Reig Jofre's Gross Profit too high?
Laboratorio Reig Jofre's current Gross Profit is €253.7 Mil. Overall, Laboratorio Reig Jofre has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Laboratorio Reig Jofre's Gross Profit compare to ZTS and UTHR?
Laboratorio Reig Jofre's Gross Profit of €253.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Laboratorio Reig Jofre and its competitors. Laboratorio Reig Jofre's current Gross Profit is €253.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorio Reig Jofre stock overvalued right now?
Based on GuruFocus' analysis, Laboratorio Reig Jofre (XMAD:RJF) is currently considered Fairly Valued. The stock's GF Value™ is €2.69, compared to a current price of €2.67 — trading 0.7% below its estimated fair value. The current Gross Profit is €253.7 Mil. Laboratorio Reig Jofre's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Laboratorio Reig Jofre (XMAD:RJF), the current Gross Profit is €253.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorio Reig Jofre (XMAD:RJF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorio Reig Jofre stock appears to be undervalued.
The current stock price of €2.67 is trading 0.7% below its estimated GF Value™ of €2.69.
GuruFocus considers Laboratorio Reig Jofre to be Fairly Valued.
Key valuation signals for XMAD:RJF:
Gross Profit: €253.7 Mil
GF Value™: €2.69 vs. price of €2.67 (0.7% below fair value)
No single metric tells the full story. See the XMAD:RJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorio Reig Jofre SA is a healthcare and pharmaceutical developing company. The company focuses on the development of technological-specialization products (antibiotics and injectable products); therapeutic-specialization products in the areas of dermatology, gynecology and respiratory; and consumer healthcare products. It has a broad portfolio of products that the company divides into three categories: products from specialized technology such as antibiotics, injectable, and freeze-dried products.
81GF Score
Get the complete analysis for XMAD:RJF
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:RJF has been successfully added to your 
